Skip to main content
SpringerLink
Log in

Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The clinical effectiveness and safety of vaginal micronized progesterone treatment in mastodynia were evaluated in a double-blind placebo controlled study. Eighty regularly menstruating worn-’ en affected by severe cyclical mastodynia were randomly assigned to two groups of 40 patients. One group was treated for 6 cycles from the 19th to the 25th day of the cycle with 4 g of vaginal cream containing 2.5% natural progesterone. The other group was similarly treated with placebo. The treatment was preceded by a control cycle. All patients reported every day their breast pain on a 100 mm visual linear analogue scale (VAS). The response of breast tenderness and nodularity to treatment was assessed by clinical examination. Vaginal progesterone resulted significantly more efficacious than placebo in reducing mean ratings of breast pain on VAS and mean scores of breast tenderness to touch. Success of treatment, defined as reduction greater than 50% of basal mean score of breast pain on VAS, was achieved in the 64.9% of patients treated with progesterone and in the 22.2% of patients receiving placebo (p<0.01). Conversely, at the end of treatment, the improvement in breast nodularity showed a not statistically significant difference between the two groups. No major side-effects were detected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wisbey J.R., Kumar S., Mansel R.E., Preece P.E., Pye J.K., Hughes L.E. Natural history of breast pain. Lancet 2: 672, 1983.

    Article  CAS  PubMed  Google Scholar 

  2. Fentiman I.S., Caleffi M., Bram K., Chandary M.A., Hayward J.L. Double blind controlled trial of tamoxifen therapy for mastalgia. Lancet 1: 287, 1986.

    Article  CAS  PubMed  Google Scholar 

  3. Sitruk-Ware R., Sterkers N., Mowszowicz I., Mauvais-Jarvis P. Inadeguate corpus luteum function in women with benign breast diseases. J. Clin. Endocrinol. Metab. 44:771, 1977.

    Article  CAS  PubMed  Google Scholar 

  4. England P.C., Skinner L.G., Cottrell K.M., Sellwood R.A. Sex hormones in breast disease. Br. J.Surg. 62:806, 1975.

    Article  CAS  PubMed  Google Scholar 

  5. Walsh P.V., Bulbrook R.D., Stell P.M., Wang D.Y., McDicken I.W., George W.D. Serum progesterone concentration during the luteal phase in women with benign breast disease. Eur. J. Cancer. Clin. Oncol. 20:1339, 1984.

    Article  CAS  PubMed  Google Scholar 

  6. Read G.F., Bradley S.A., Wilson D.W., George W.D., Griffiths K. Evaluation of luteal-phase salivary progesterone levels in women with benign breast disease or primary breast cancer. Eur. J. Clin. Oncol. 21: 9, 1985.

    Article  CAS  Google Scholar 

  7. Wang D.Y., Fentiman I.S. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res. Treat. 6:5, 1985.

    Article  CAS  PubMed  Google Scholar 

  8. Kumar S., Mansel R.E., Hughes L.E., Woodhead J.S., Edwards C.A., Scanlon M.F., Newcombe R.G. Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 53:1311, 1984.

    Article  CAS  PubMed  Google Scholar 

  9. Kumar S., Mansel R.E., Wilson D.W., Read G.F., Truran P.L., Hughes L.E., Griffiths K. Daily salivary progesterone levels in cyclical mastalgia patients and their controls. Br. J.Surg. 73:260, 1986.

    Article  CAS  PubMed  Google Scholar 

  10. Rannevik G., Doberl A., Gershagen S., Rasmussen T.H., Tobiassen T. Elevated serum concentrations of sex hormone binding globulin in fibrocystic breast disease. In: Angeli A., Bradlow H.L., Dogliotti L. (Eds.), Endocrinology of cystic breast disease. Raven Press, New York, 1983, p. 127.

    Google Scholar 

  11. Carlstrom K., Doberl A., Gershagen S., Rannevik G., Rasmussen T.H., Tobiassen T. Elevated peripheral levels of androgens and of some steroid sensitive plasma proteine in patients with severe fibrocystic breast disease. Acta Obstet. Gynecol. Scand. (Suppl.) 23:157, 1984.

    Article  Google Scholar 

  12. Greenblatt R.B., Nezhat C., Ben Nun I. The treatment of benign breast disease with danazol. Fertil. Steril. 34:242, 1980.

    CAS  PubMed  Google Scholar 

  13. Pye J.K., Mansel R.E., Hughes L.E. Clinical experience of drug treatments for mastalgia Lancet 2: 373, 1985.

    Article  CAS  PubMed  Google Scholar 

  14. Andrews W.C. Hormonal management of fibrocystic disease of the breast. J. Reprod. Med. 35:87, 1990.

    CAS  PubMed  Google Scholar 

  15. Ricciardi I., Ianniruberto A. Tamoxifen-induced regression of benign breast lesion. Obstet. Gynecol. 54:80, 1979.

    Article  CAS  PubMed  Google Scholar 

  16. Shaaban M.M., Morad F., Hassan A-el-R. Treatment of fibrocystic mastopathy by an anti-estrogen, tamoxifen. Int. J. Gynecol. Obstet. 73:348, 1980.

    Google Scholar 

  17. Mansel R.E., Preece P.E., Hughes L.E. A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br. J. Surg. 65:724, 1978.

    Article  CAS  PubMed  Google Scholar 

  18. Blichert-Toft M., Anderson A.N., Henriksen O.B., Migind T. Treatment of mastalgia with bromocriptine: a double blind cross-over study. Br. Med. J. 1: 237, 1979.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Vorherr H. Fibrocystic breast disease: Pathophysiology, pathomorphology, clinical picture and management. Am. J. Obstet. Gynecol. 154:161, 1986.

    Article  CAS  PubMed  Google Scholar 

  20. Ruf H., Codaccioni J.L., Serment H. Le norethynodrel dans le syndrome premenstruel et les dysplasies mammaires. Bull. Fed. Gynec. Obstet. Franc. 76:587, 1964.

    Google Scholar 

  21. Mauvais-Jarvis P. Current therapeutic data concerning mastodynia and benign mastopathy. Therapeutique 43:575, 1972.

    Google Scholar 

  22. Meyrick R.L., Smith I. Benign breast swelling. Br. Med. J. 2:585, 1972.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Colin C., Gaspard V., Lambotte R. Relationship of mastodynia with its endocrine envi-roment and treatment in a double blind trial with lyne-strol. Archiv. fur Gynaekologie 225: 7, 1978.

    Article  CAS  Google Scholar 

  24. Bradley D.D., Wingerd J., Petitti D.B. Serum high density lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. N. Engl. J. Med. 299:17, 1978.

    Article  CAS  PubMed  Google Scholar 

  25. Hirnoven E., Malkonen M., Manninem V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N. Engl. J. Med. 304:560, 1981.

    Article  Google Scholar 

  26. Fahraeus L., Larsson-Cohn U., Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur. J. Clin. Invest. 30:447, 1983.

    Article  Google Scholar 

  27. Ottoson V.B., Johansson B.G., Von Schoultz B. Subtraction of high-density lipoprotein cholesterol during estrogen replacement therapy: comparison between progestogens and natural progesterone. Am. J. Obstet. Gynecol. 151: 746, 1985.

    Article  Google Scholar 

  28. McFadyen I.S., Raab G.M., Maclntyre C.C.A., Forrest A.P.M. Progesterone cream for cyclic breast pain. Br. Med. J. 298:931, 1989.

    Article  CAS  Google Scholar 

  29. Maxson W.B., Hargrove J.T. Bioavailability of oral micronized progesterone. Fertil. Steril. 44: 622, 1985.

    CAS  PubMed  Google Scholar 

  30. Villaneuva B., Casper R.F., Yen S.S.C. Intravaginal administration of progesterone: enhanced after estrogen treatment. Fertil. Steril. 35:433, 1981.

    Google Scholar 

  31. Nappi C., Mercorio F., Affinito P., Lepore L., Montemagno U. Vaginal administration of natural progesterone in premenopausal women with endometrial hyperplasia. In: Genazzani A.R., Petraglia F. and Volpe A. (Eds.), Research Reports on Gynecology and Obstetrics. The Parthenon Publishing Group, Carnforth, 1989, p. 543.

    Google Scholar 

  32. Haagensen CD., Bodian C., Haagensen D.E.Jr. Fibrous disease of the breast. In: Breast carcinoma. Risk and detection. W.B. Saunders Company, Philadelphia, 1981, p. 132.

    Google Scholar 

  33. Hsueh A.J.W., Peck E.J., Clark J.H. Progesterone antagonism of the estrogen receptor and estrogen-induced uterine growth. Nature 254: 337, 1975.

    Article  CAS  PubMed  Google Scholar 

  34. Tseng L., Gurpide E. Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology 97: 825, 1975.

    Article  CAS  PubMed  Google Scholar 

  35. Prudhomme J.F., Malet C., Gompel A., Lalardne J.P., Ochoa C., Boue A., Mauvais-Jarvis P., Kutten F. 17β-hydroxysteroid dehydrogenase (E2DH) activity in human breast epithelial cell and fibroblast cultures. Endocrinology 114:1483, 1984.

    Article  CAS  Google Scholar 

  36. Gompel A., Malet C., Spritzer P., Lalardrie J.P., Kutten F., Mauvais-Jarvis P. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J. Clin. Endocrinol. Metab. 63:1174, 1986.

    Article  CAS  PubMed  Google Scholar 

  37. Morville R., Dray F., Reyner J., Barrat J. Biodisponibilité de la progesterone naturelle admin-istrée par voie orale. Mésure des concentrations du stéroide dans le plasma, l’endomètre et le tissue mammaire. J. Gynecol. Obstet. Biol. Repr. 11:355, 1982.

    CAS  Google Scholar 

  38. Krause W., Wichmann U., Horn W. Resorption of progesterone through the intact skin of the breast in comparison with other body regions Geburtshilfe Frauenheilkd 47:562, 1987.

    Article  CAS  PubMed  Google Scholar 

  39. Bucks D.A., McMaster J.R., Maibach H.I., Guy R.H. Biovailability of topically administered steroids: a “mass balance” technique. J. Invest. Dermatol. 91: 29, 1988.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Endocrinologia Ginecologica, Università di Torino, Torino, Italy

    C. Nappi

  2. Istituto di Ginecologia ed Ostetricia, II Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”, via Pansini 5, 80131, Napoli, Italy

    Pietro Affinito, C. Di Carlo & U. Montemagno

  3. Angelini F., A.C.R.A.F., Roma, Italy

    G. Esposito (Direzione Medica)

Authors
  1. C. Nappi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pietro Affinito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Di Carlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Montemagno
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nappi, C., Affinito, P., Di Carlo, C. et al. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest 15, 801–806 (1992). https://doi.org/10.1007/BF03348808

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03348808

Key-words

Search

Navigation